MFG
INFI

Merit Financial Group’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Merit Financial Group’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-20,600
Closed -$11.4K – 743
2022
Q4 		$11.4K Hold
20,600
– – ﹤0.01% 685
2022
Q3 		$25K Hold
20,600
– – ﹤0.01% 554
2022
Q2 		$13K Buy
+20,600
New +$15.8K ﹤0.01% 569

Other funds holding INFI

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Merit Financial Group's INFI Position: Q1 2023 in Review

Merit Financial Group sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q1 2023, closing a stake of 20,600 shares — an estimated $11.4K sold.

Merit Financial Group first reported a position in INFI in Q2 2022 and held it in 3 quarters. The position peaked at $25K in Q3 2022. 53 funds tracked by Wall St. Rank hold INFI as of Q1 2023.

  • Merit Financial Group reported no remaining Infinity Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
  • Merit Financial Group sold 20,600 Infinity Pharmaceuticals, Inc. shares in Q1 2023, an estimated $11.4K.
  • Merit Financial Group first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2022 and held it in 3 quarters.
  • Merit Financial Group's Infinity Pharmaceuticals, Inc. position peaked at $25K in Q3 2022.
  • 53 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q1 2023.

Based on Merit Financial Group's 13F filing for Q1 2023, filed 24 Apr 2023.